3 months to introduce 5 innovative products! Idea Di medicine in the research pipeline is accelerating expansion

The two new drugs introduced this time are Galinpepimut-S (GPS) and the seven-priced next-generation Galinpepimut-S plus (GPS Plus).
, GPS is an innovative new cancer immunotherapy drug targeting WT1 (Wilms Tumor Protein) for the treatment of WT1 antigen over-expression of malignant hematomas and solid tumors.
It consists of 4 peptide chains, up to 25 antigens, suitable for the vast majority of human lewd cell tissue compatible antigen (HLA) types worldwide, can stimulate their own immune system strong immune response to WT1 antigens, monotherapy or combination therapy can effectively kill tumor cells in the body and strengthen the immune surveillance of tumor cells, is expected to become the target of the first innovative drug (first-in-class).
another GPS plus for the seven-price version of GPS, adding three peptide segments to the GPS in order to achieve better treatment results and fuller HLA coverage. according to
, GPS and GPS plus are mature freeze-dried preparations, using off-the-skin injection administration, which can be used as a single drug for maintenance therapy in low-risk clinical situations, but also with PD-1/PD-L1 antibodies and other therapeutic drugs combined to improve efficacy.
clinical trial results show that GPS has a high immunogenicity, can delay the recurrence of disease, and adverse events are mainly weak local reactions at the injection site.
currently, a Phase 3 clinical trial of GPS monodring for acute myeloid leukemia (AML) is under way, and a Phase 1/2 clinical trial of a drug in union with PD-1/PD-L1 antibodies is under way.
, it also received fast-track or orphan drug qualifications from the FDA and the European EMA for adaptations such as multiple myeloma (MM), AML, and malignant thoracic mesothelioma (MPM), respectively.
gps plus is about to enter the clinical development stage.
it is worth mentioning that in a partnership with Aravive in November, Wedi Pharmaceuticals intends to obtain exclusive authorization for clinical development and commercialization of the new cancer drug AVB-500 in the field of cancer in Greater China for over $210 million.
AVB-500 is a specific high affinity Fc fusion protein specific to GAS6, and is also a new GAS6-AXL signal pathens inhibitor, which is about to enter Phase 3 registered clinical studies.
and the two innovative analgesics RMX1001 and RMX1002, introduced from Haihe in October, have the potential to replace traditional nonsteroidal anti-inflammatory drugs and become new analgesics, according to an earlier press release, having previously completed Phase 1 clinical studies in China.
, the RMX1001 is a next-generation Cox-2 inhibitor and the RMX1002 is an EP4 subject antagonist.
References: The innovative drug for clinical Stage III oncology immunotherapy is authorized exclusively in Greater China.Retrieved Dec 7,2020, from 3D Medicines Official Micro ( 2 ) Thought Di Pharmaceuticals has been granted exclusive development and commercialization of the NASDAQ-listed Aravive anti-cancer drug AVB-500 Greater China. Retrieved Nov 11, 2020, From snr. Retrieved Oct 27, 2020, from Source: Supplied